• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Pregnancy >Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns
【24h】

Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns

机译：子痫前期的临床表现及蛋白质及其甲基化产物作为生物标志物在孕妇和子痫前期及其新生儿中的诊断价值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Preeclampsia (PE) is a disorder which affects 1-10% of pregnant women worldwide. It is characterised by hypertension and proteinuria in the later stages of gestation and can lead to maternal and perinatal morbidity and mortality. Other than the delivery of the foetus and the removal of the placenta, to date there are no therapeutic approaches to treat or prevent PE. It is thus only possible to reduce PE-related mortality through early detection, careful monitoring, and treatment of the symptoms. For these reasons the search for noninvasive, blood-borne, or urinary biochemical markers that could be used for the screening, presymptomatic diagnosis, and prediction of the development of PE is of great urgency. So far, a number of biomarkers have been proposed for predicting PE, based on pathophysiological observations, but these have mostly proven to be unreliable and inconsistent between different studies. The clinical presentation of PE and data gathered for the biochemical markers placental growth factor (PlGF), soluble Feline McDonough Sarcoma- (fms-) like tyrosine kinase-1 (sFlt-1), asymmetric dimethylarginine (ADMA), and methyl-lysine is being reviewed with the aim of providing both a clinical and biochemical understanding of how these biomarkers might assist in the diagnosis of PE or indicate its severity.
机译：先兆子痫（PE）是一种疾病，影响全世界1-10％的孕妇。它的特征是在妊娠后期出现高血压和蛋白尿，并可能导致孕产妇和围产期发病和死亡。除了胎儿的输送和胎盘的去除，迄今为止，还没有治疗或预防PE的治疗方法。因此，只有通过及早发现，仔细监测和治疗症状，才能降低与PE相关的死亡率。由于这些原因，寻找可用于筛查，症状前诊断和预测PE发展的非侵入性，血源性或尿液生化标记物非常重要。到目前为止，已经根据病理生理学观察结果提出了许多生物标志物来预测PE，但是在不同研究之间，多数生物标志物被证明是不可靠和不一致的。 PE的临床表现和针对胎盘生长因子（PlGF），可溶性猫科动物麦克唐纳肉瘤（fms-）像酪氨酸激酶1（sFlt-1），不对称二甲基精氨酸（ADMA）和甲基赖氨酸的生化指标是为了提供有关这些生物标记物如何帮助诊断PE或表明其严重性的临床和生化理解，我们对其进行了综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号